替罗非班联合经皮冠脉介入治疗急性冠脉综合征的临床观察  

Clinical Effects of Tirofiban in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

作　　者：孙显东[1] 杨波[1] 计晓玲[1] 

机构地区：[1]赤峰市医院心内科,内蒙古赤峰024000

出　　处：《内蒙古医学杂志》2012年第6期679-682,共4页Inner Mongolia Medical Journal

摘　　要：目的:评价替罗非班联合经皮冠状动脉介入(PCI)治疗急性冠脉综合征(ACS)的疗效与安全性。方法:360例ACS需PCI治疗的患者,随机分为替罗非班组(180例)和依诺肝素组(180例)。治疗组PCI术后即刻给予替罗非班10.0μg/kg弹丸式注射,随后以0.15μg/(kg.min)持续静脉泵入24 h。用药后12、24、48 h观察两组患者TnI值改变及不良反应发生情况;术后24 h及用药后3、6个月观察两组联合心脏事件(MACE)。结果:替罗非班组与依诺肝素组比较术后24 h、3、6个月发生的联合心脏事件差异无统计学意义(P>0.05)。术后12 h替罗非班组肌钙蛋白水平明显低于依诺肝素组,差异有统计学意义,提示替罗非班对心功能有良性影响。两组均无严重出血事件发生,替罗非班组有1例血小板减少症发生。结论:盐酸替罗非班联合PCI治疗ACS可减少心肌损伤,对预后有良性影响,且安全性较好,无严重并发症发生。Objective：To evaluate the clinical effects and safety of tirofiban in patients with acute coronary syndrome（ACS） undergoing percutaneous coronary intervention（PCI）. Methods： This is a randomized control trial, 360 patients were randomly assigned in two groups. After PCI a bolus of tirofiban （ 10.0 μg/kgwas admin- istered intravenously, then an intravenous infusion of tirofiban 0.15 μg/（kg·min）was started and maintained for 24 hours in tirofiban group. The values of troponin I（TnI） and side effect were recorded within 12, 24, 48h after randomization, Follow up major adverse cardiac events on 24 hour, at 3 and 6 months after randomization. Re- sults： The rates of MACE among two groups had no differences on 24 hour, at 1 month and 6 monthes follow - up（P 〉0.05）. The values of TnI were found significant differences on 12 hour（P 〈 0.05）, the result hints tirofiban has a optimum effect on heart function. There was no major bleeding and only one thrombocytopenia in tirofiban group. Conclusion： Tirofiban made in China has a optimum effect on heart function, and can improve the prognosis safely in patients with acute coronary syndrome undergoing PCI.

关 键 词：替罗非班 急性冠状动脉综合征 血管成形术 

分 类 号：R541.4[医药卫生—心血管疾病]